Literature DB >> 7935333

Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid.

J C Pinto1, F Potié, K C Rice, D Boring, M R Johnson, D M Evans, G H Wilken, C H Cantrell, A C Howlett.   

Abstract

The cannabinoid receptor in brain (CB1) specifically binds delta 9-tetrahydrocannabinol, the predominant central nervous system-active component of marijuana. An eicosanoid found in brain, N-(2-hydroxyethyl)arachidonylamide (anandamide), binds to CB1 with similar affinity. This report considers structure-activity requirements for a series of novel amides and rigid hairpin conformations typified by N-(2-hydroxyethyl)prostaglandin amides, assayed with phenylmethylsulfonyl fluoride inactivation of esterases/amidases. Arachidonyl esters were 30-fold less potent than N-(2-hydroxyethyl)arachidonylamide, showing a rank order of potency of methyl = ethyl > propyl = isopropyl. Within the N-(hydroxyalkyl)arachidonylamide series, a one-carbon increase in chain length increased the potency 2-fold, but continued extension decreased affinity. Substituting the amide for the N-(2-hydroxyethyl)amide function produced a 4-fold loss of affinity. The N-(propyl)-, N-(butyl)-, and N-(benzyl)arachidonylamide derivatives exhibited a 3-fold increase, no change, and a 5-fold decrease, respectively, in affinity, compared with N-(2-hydroxyethyl)arachidonylamide. Both the methoxy ether and the formamide derivatives suffered > 20-fold loss of potency, compared with N-(2-hydroxyethyl)arachidonylamide. N-(2-Aminoethyl)arachidonylamide interacted poorly with CB1. At 100 microM, N-(2-hydroxyethyl)amide analogs of prostaglandin E2, A2, B2, and B1 failed to alter [3H]CP55940 binding to CB1. N-(2-Hydroxyethyl)arachidonylamide inhibited adenylate cyclase with lesser potency but with similar efficacy, compared with desacetyllevonantradol. Extending the length of the hydroxyalkyl moiety by one carbon increased the apparent potency by 1 order of magnitude. The N-(propyl) derivative exhibited a 5-fold greater potency than did the N-(2-hydroxyethyl) analog. It appears that the bulk and length of the moiety appended to arachidonic acid are more important determinants of affinity for CB1 than is hydrogen-bonding capability.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7935333

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  24 in total

1.  Structural determinants in the second intracellular loop of the human cannabinoid CB1 receptor mediate selective coupling to G(s) and G(i).

Authors:  X P Chen; W Yang; Y Fan; J S Luo; K Hong; Z Wang; J F Yan; X Chen; J X Lu; J L Benovic; N M Zhou
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

2.  Antitumorigenic Properties of Omega-3 Endocannabinoid Epoxides.

Authors:  Jahnabi Roy; Josephine E Watson; In Sup Hong; Timothy M Fan; Aditi Das
Journal:  J Med Chem       Date:  2018-06-26       Impact factor: 7.446

3.  Endocannabinoids block status epilepticus in cultured hippocampal neurons.

Authors:  Laxmikant S Deshpande; Robert E Blair; Julie M Ziobro; Sompong Sombati; Billy R Martin; Robert J DeLorenzo
Journal:  Eur J Pharmacol       Date:  2006-11-22       Impact factor: 4.432

4.  Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide.

Authors:  D L Boger; J E Patterson; X Guan; B F Cravatt; R A Lerner; N B Gilula
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

Review 5.  Astrocyte Ca²⁺ signalling: an unexpected complexity.

Authors:  Andrea Volterra; Nicolas Liaudet; Iaroslav Savtchouk
Journal:  Nat Rev Neurosci       Date:  2014-05       Impact factor: 34.870

6.  Approaches to Assess Biased Signaling at the CB1R Receptor.

Authors:  Robert B Laprairie; Edward L Stahl; Laura M Bohn
Journal:  Methods Enzymol       Date:  2017-07-05       Impact factor: 1.600

Review 7.  The expanding field of cannabimimetic and related lipid mediators.

Authors:  Heather B Bradshaw; J Michael Walker
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

Review 8.  Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.

Authors:  Dennis J Sholler; Marilyn A Huestis; Benjamin Amendolara; Ryan Vandrey; Ziva D Cooper
Journal:  Pharmacol Biochem Behav       Date:  2020-10-18       Impact factor: 3.533

Review 9.  Prostamides (prostaglandin-ethanolamides) and their pharmacology.

Authors:  D F Woodward; Y Liang; A H-P Krauss
Journal:  Br J Pharmacol       Date:  2007-08-27       Impact factor: 8.739

10.  Synthesis and cannabinoid receptor binding activity of conjugated triene anandamide, a novel eicosanoid.

Authors:  M L Wise; K Soderstrom; T F Murray; W H Gerwick
Journal:  Experientia       Date:  1996-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.